Dermatophytic Onychomycosis Treatment Market to Hit USD 9.52 Billion by 2032; Strong Presence of Potential Pipeline Candidates to Proliferate Market Growth

The global dermatophytic onychomycosis treatment market size was valued at USD 5.34 billion in 2024. The market is projected to grow from USD 5.74 billion in 2025 to USD 9.52 billion by 2032, exhibiting a CAGR of 7.5% during the forecast period. The expansion can be credited to the growing shift toward topical dermatophytic onychomycosis treatment solutions. Patients diagnosed with liver and heart disease are not prescribed oral anti-fungal drugs as they are associated with liver damage.

Fortune Business Insights™ presents this information in its report, titled “Dermatophytic Onychomycosis Treatment Market Size, Share & Industry Analysis, By Product Type (Tablets and Nail Paints), By Route of Administration (Oral and Topical), By Type (Prescribed and Over-the-Counter (OTC)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Channels), and Regional Forecast, 2025-2032”.

Decline in Patient Visits to Clinics Hindered the Market Growth Amid the Pandemic

The COVID-19 pandemic negatively impacted the dermatophytic onychomycosis treatment market growth. Dermatology clinics were temporarily closed during the pandemic, which reduced patient visits and postponed diagnoses, impeding the market growth. In addition, tightening regulations for non-essential healthcare services coupled with lockdown impositions negatively influenced the market growth. However, the reopening of clinics helped the market gain normalcy in the post-pandemic period.

Bausch Health Companies Inc. Secured the American Podiatric Medical Association Approval to Gain a Competitive Edge

In December 2021, Bausch Health Companies Inc. got clearance from the American Podiatric Medical Association (APMA) for Jublia. In 2020, the company also secured extended approval from the U.S. FDA for the treatment of pediatric patients aged six years and above suffering from onychomycosis.

Market Value to Grow Owing to Robust Drug Pipeline

The market growth is driven by the presence of a strong drug pipeline. Pharmaceutical companies are investing heavily in R&D to develop novel therapeutics due to the growing prevalence of dermatophytic onychomycosis. In addition, compounds with deeper penetration into the nails are being researched actively by several companies to cure this condition.

However, the lack of knowledge of symptoms of dermatophytic onychomycosis may restrain market growth.

Leading Players Focus on Partnerships to Reinforce their Market Position

The prominent market players are focusing on different competitive strategies to capture the largest market share. Some of these strategies include joint ventures, mergers and acquisitions, and others. Several companies are also entering partnerships to expand their market hold.

Key Players Profiled:

• Bausch Health Companies Inc. (Canada)


• Pfizer Inc. (U.S.)


• Galderma (Switzerland)


• GlaxoSmithKline plc (U.K.)


• Janssen Pharmaceuticals, Inc. (U.S.)


• Cipla Inc. (India)


• Kaken Pharmaceuticals Co., Ltd. (Japan)

Notable Industry Development

July 2021: Almirall S.A. and Kaken Pharmaceutical signed a distribution and license agreement, under which Almirall was granted exclusive rights by Kaken Pharmaceutical to develop and commercialize topical antifungal efinaconazole in Europe. This strategy helped Almirall S.A. expand its geographical presence in Europe.

Further Report Findings

• Based on region, the market is divided into Asia Pacific, Europe, North America, and the rest of the world.

Table of Segmentation